Brian Mehling, M.D. Presents at International Conference and Expo on Musculoskeletal Disease and Regeneration in Chicago

Share Article

The conference was held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem cell therapy for arthritis and joint injuries.

Dr. Brian Mehling

American orthopedic surgeon and internationally recognized stem cell researcher, founder of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International Conference and Expo on Musculoskeletal Disease and Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on stem cell therapy for arthritis and joint injuries.

“Stem cell treatments are, without a doubt, the future of medicine and we believe their role in treatments will become the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services,” Dr. Mehling stated. “It is important that doctors and medical professionals are educated on what direction the world will take in regard to stem cell research and therapies. The possibilities in stem cell research and regenerative medicine are endless. It is crucial for physicians to be aware of the therapies available for patients with different chronic conditions, disorders, and acute diseases.”

Blue Horizon International is currently offering adipose-derived stem cell treatment for joint diseases at Malacky Hospital in Slovakia. Stem cells from adipose tissue can be easily obtained under local anesthesia. Stem cell therapy for arthritis and joint injures include the following steps: removal of adipose tissue under local anesthesia; processing of lipoaspirate, isolation of Stromal Vascular Fraction (SVF) and administration of preparation into the hip joint. In addition to mesenchymal stem cells, the cells isolated from adipose and connective tissues include other cells that: suppress the inflammatory response, contribute to the regeneration, create an optimal environment for receiving own stem cells, which prevent further degeneration of damaged tissues and cells in the new environment.

"We have treated more than 100 patients so far, all with outstanding results. Stem cells are a great option when the patient is not a good candidate for traditional forms of treatment, such as invasive surgery or other treatment modalities," said Mgr Renata Mihalyova, general manager of Blue Horizon International Slovakia.

About Mehling Orthopedics
Mehling Orthopedics performs complex orthopedic fracture surgeries, including high velocity fractures, open fractures and complex pelvic ring injuries as well as general orthopedic and sports medicine surgeries. Their team of experts delivers specialized care for orthopedic traumatic injuries. With all doctors certified by the American Board of Orthopedic Surgeons, they are committed to providing the finest medical care possible. For more information, please visit http://www.MehlingOrthopedics.com.

About Blue Horizon International
Blue Horizon International is a healthcare consulting company with a unique mission that combines treatment, research and philanthropic efforts. Across the globe quality care and services for medical treatments are provided along with resources needed to assist children and adults who are medically underserved. For more information, please visit http://www.BlueHorizonInternational.com.

About BHI Therapeutic Sciences, LLC
BHI Therapeutic Sciences, LLC is currently offering cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and is fully licensed by the Ministry of Health of the Slovak Republic. For more information, please visit http://www.BHIsciences.com

About OMICS International
OMICS International and its subsidiaries including iMedPub LLC and Conference Series LLC organize 3,000+ Conferences across USA, Europe & Asia with support from 1,000 more scientific societies and publishes 700+ Open Access Journals which contains over 50,000 eminent personalities, reputed scientists as editorial board members.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rubenstein
Public Relations
+1 (212) 805-3057
Email >
Visit website